{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-012324","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.953376+00:00","generated_at":"2026-06-16T02:21:58.469469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OPKO Health Q1 revenue down 28% YoY to $237.6M; net loss narrows to $0.02/share","bullets":["Pharmaceuticals revenue up to $40.4M (vs $36.6M) driven by Rayaldee and IP transfers including $50M Merck upfront.","Diagnostics revenue plunged to $132.4M from $286.6M due to lower COVID testing and GeneDx sale; operating loss of $40M.","ModeX entered license deal with Merck for EBV vaccine MDX-2201; potential milestones up to $872.5M plus royalties.","Net loss improved to $18.3M ($0.02/share) from $55.4M ($0.08/share) in Q1 2022; cash $110.8M not including $50M April payment.","Rayaldee sales grew to $6.6M from $5.1M; NGENLA approved in 41 countries, sales underway in 17."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-012324","json":"https://secwatch.observer/filing/0001437749-23-012324.json","markdown":"https://secwatch.observer/filing/0001437749-23-012324.md","text":"https://secwatch.observer/filing/0001437749-23-012324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/0001437749-23-012324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/opk20230425_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:21:58.469469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79f25d9bc2f321c9e06e98c12b5c18d1c72f76b2","claim":"OPKO HEALTH, INC. reported the three months ended March 31, 2023 results: revenue $237.6 million, net income $18.3 million, EPS $0.02 per share.","evidence_excerpt":"Consolidated total revenues for the first quarter of 2023 were $237.6 million compared with $329.2 million for the comparable period of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/0001437749-23-012324-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$237.6 million"},{"label":"Net income","value":"$18.3 million"},{"label":"EPS","value":"$0.02 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}